Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Contacts
Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
Mentioned In This Article
Latest News
| Nov-13 | |
| Nov-13 | |
| Nov-12 | |
| Nov-12 | |
| Nov-10 |
Vir Biotechnologys hepatitis D drug scores in Phase II and Phase III trials
VIR
Clinical Trials Arena
|
| Nov-09 | |
| Nov-09 | |
| Nov-09 | |
| Nov-09 | |
| Nov-08 | |
| Nov-08 | |
| Nov-08 | |
| Nov-05 | |
| Nov-04 | |
| Nov-04 |
